01605nas a2200205   4500008003900000245005100039210005100090260000800141300001300149490000600162520093200168653004501100653001101145653004701156653004601203653004801249653004501297100001201342856004501354       1993                          d00aTumors after renal and cardiac transplantation0 aTumors after renal and cardiac transplantation  cApr  a431 - 450 v73 aOrgan transplant recipients treated with immunosuppressive therapy are prone to develop malignancies particularly squamous cell carcinomas of the skin, non-Hodgkin's lymphomas, Kaposi's sarcomas, carcinomas of the vulva and perineum, in situ carcinomas of the uterine cervix, renal carcinomas, hepatomas, and various sarcomas. The earliest tumors to appear are the Kaposi's sarcoma at an average of 21 months after transplantation, and the latest are carcinomas of the vulva and perineum, at an average of 112 months after transplantation. The tumors that develop in cardiac allograft recipients compared with renal transplant recipients are predominantly non-Hodgkin's lymphomas and more rarely, skin, uterine cervical and vulvar tumors. Major factors accounting for these differences are the intensity of immunosuppressive therapy given to the cardiac patients and the much longer follow-up of the renal allograft recipients.10aHeart Transplantation / *adverse effects10aHumans10aImmunosuppressive Agents / adverse effects10aKidney Transplantation / *adverse effects10aNeoplasms / diagnosis / *etiology / therapy10aResearch Support, U.S. Gov't, Non-P.H.S.1 aPenn, I  uhttps://notifylibrary.org/reference/1189